ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006.

作者信息

Hilger R A, Kredke S, Hedley D, Moeller J G, Bauer R J, Stellberg W, Seeber S, Scheulen M E, Strumberg D

机构信息

Universitätsklinikum Essen, Innere Klinik und Poliklinik (Tumorforschung), Abteilung Pharmakologie Antineoplasticher Substanzen, Essen, Germany.

出版信息

Int J Clin Pharmacol Ther. 2002 Dec;40(12):567-8. doi: 10.5414/cpp40567.

DOI:10.5414/cpp40567

PMID:12503816

Abstract

摘要

相似文献

ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006.

Int J Clin Pharmacol Ther. 2002 Dec;40(12):567-8. doi: 10.5414/cpp40567.

Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.

Int J Clin Pharmacol Ther. 2002 Dec;40(12):580-1. doi: 10.5414/cpp40580.

Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006.

Int J Clin Pharmacol Ther. 2004 Nov;42(11):648-9. doi: 10.5414/cpp42648.

Activation of cytosolic phospholipase A2alpha by epidermal growth factor (EGF) and phorbol ester in HeLa cells: different effects of inhibitors for EGF receptor, protein kinase C, Src, and C-Raf.

J Pharmacol Sci. 2009 Oct;111(2):182-92. doi: 10.1254/jphs.09201fp. Epub 2009 Sep 26.

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Cancer Res. 2004 Oct 1;64(19):7099-109. doi: 10.1158/0008-5472.CAN-04-1443.

Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors.

Clin Colorectal Cancer. 2003 May;3(1):16-8. doi: 10.1016/s1533-0028(11)70463-7.

Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.

Mol Cancer Ther. 2008 Apr;7(4):890-6. doi: 10.1158/1535-7163.MCT-07-0518.

Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.

Int J Clin Pharmacol Ther. 2003 Dec;41(12):618-9. doi: 10.5414/cpp41618.

Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.

J Biol Chem. 2007 Oct 5;282(40):29230-40. doi: 10.1074/jbc.M703461200. Epub 2007 Jul 30.

In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.

Endocr Relat Cancer. 2011 Jul 1;18(4):401-12. doi: 10.1530/ERC-10-0258. Print 2011 Aug.

引用本文的文献

Kinase inhibitors: look beyond the label on the bottle.

Cancer Drug Resist. 2019 Dec 19;2(4):1032-1043. doi: 10.20517/cdr.2019.80. eCollection 2019.

Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.

PLoS One. 2012;7(5):e37424. doi: 10.1371/journal.pone.0037424. Epub 2012 May 16.

Molecular prescreening to select patient population in early clinical trials.

Nat Rev Clin Oncol. 2012 Apr 3;9(6):359-66. doi: 10.1038/nrclinonc.2012.48.

Integrating molecular docking, DFT and CoMFA/CoMSIA approaches for a series of naphthoquinone fused cyclic α-aminophosphonates that act as novel topoisomerase II inhibitors.

J Mol Model. 2011 Aug;17(8):1899-909. doi: 10.1007/s00894-010-0898-y. Epub 2010 Nov 25.

Raf kinases: function, regulation and role in human cancer.

Biochim Biophys Acta. 2007 Aug;1773(8):1196-212. doi: 10.1016/j.bbamcr.2007.05.001. Epub 2007 May 22.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验